Teva Pharmaceutical Industries Spon Ads Each Rep 1 Ord Shs (TEVA) Stock
Global generic drug manufacturer with specialty medicines. Here's the price, business snapshot, and what's worth knowing about Teva Pharmaceutical Industries Spon Ads Each Rep 1 Ord Shs in June 2026.
Teva Pharmaceutical Industries Ltd (TEVA) is a global pharmaceutical company best known for its large generics business and select specialty medicines. With a market capitalisation near $22 billion, Teva supplies a broad range of off‑patent medicines alongside branded treatments in areas such as central nervous system disorders. The company has undergone significant restructuring in recent years to cut costs, manage debt and refocus R&D. Key investor considerations include pricing pressure in generics, patent cliffs for older products, ongoing litigation and the balance sheet after past acquisitions. At the same time, scale in manufacturing, a diversified product mix and potential upside from speciality drugs or successful pipeline assets can support recovery. Investors should weigh Teva’s income statement trends, cash generation, debt reduction progress and the regulatory environment. This is general information for educational purposes only and not personalised investment advice; stock prices can fall as well as rise.
Why It’s Moving
Analyst optimism drives TEVA's 2026 outlook as pipeline breakthroughs and improved fair value estimates outweigh regional volatility concerns
- ["Multiple brokerages raised their 12-month price targets to approximately $38-$42, citing updated assumptions around long-term revenue growth and margin improvements following recent Phase 2 data."]
- ["Analysts highlighted a significant increase in the fair value estimate to nearly $38 per share, driven by optimism that the Austedo drug could reach $3 billion in peak sales following new clinical results with Sanofi."]
- ["While fair value projections have improved, experts noted that the stock's volatility remains tied to Middle Eastern conflicts, yet the consensus rating remains a strong buy due to stable near-term earnings expectations."]
Analyst optimism drives TEVA's 2026 outlook as pipeline breakthroughs and improved fair value estimates outweigh regional volatility concerns
- ["Multiple brokerages raised their 12-month price targets to approximately $38-$42, citing updated assumptions around long-term revenue growth and margin improvements following recent Phase 2 data."]
- ["Analysts highlighted a significant increase in the fair value estimate to nearly $38 per share, driven by optimism that the Austedo drug could reach $3 billion in peak sales following new clinical results with Sanofi."]
- ["While fair value projections have improved, experts noted that the stock's volatility remains tied to Middle Eastern conflicts, yet the consensus rating remains a strong buy due to stable near-term earnings expectations."]
When is the next earnings date for TEVA PHARMACEUTICAL INDUSTRIES SPON ADS EACH REP 1 ORD SHS (TEVA)?
Teva’s next earnings date is estimated for July 29, 2026, with some trackers showing a window through early August if the company does not confirm a specific release date yet. The upcoming report is expected to cover Q2 2026. Based on Teva’s recent reporting pattern, that late-July timing is the most likely.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Teva's stock with a target price of $34.71, indicating growth potential.
Financial Health
Teva is generating solid revenue and cash flow, with strong profit margins indicating good financial health.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
AbbVie
Abbvie is a research-based biopharmaceutical company that develops and markets advanced therapies to address complex medical conditions.
ASTRAZENECA PLC
AstraZeneca is a global biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing innovative medicines.
AMGEN INC
Amgen is a global biotechnology company that focuses on discovering, developing and commercializing treatments for unmet medical needs.
Baskets Featuring TEVA
U.S. Drug Manufacturing | Multi-Billion Investment Push
Johnson & Johnson is the latest major drugmaker to lower U.S. prices in exchange for tariff exemptions, joining a broad industry trend. This government-led initiative is sparking a multi-billion dollar investment wave into domestic manufacturing, creating a significant opportunity for companies supporting the U.S. pharmaceutical supply chain.
Published: 10 January 2026
Explore BasketPharma Onshoring: What's Next for US Drug Supply
Merck is investing $3 billion in a new Virginia plant, signaling a major push for domestic pharmaceutical production. This theme focuses on companies poised to benefit from the broader trend of onshoring the U.S. drug supply chain.
Published: 21 October 2025
Explore BasketDomestic Pharma Tariffs: What's Next for Investors
The U.S. government has imposed a 100% tariff on pharmaceuticals from companies lacking domestic manufacturing, aiming to reshore production. This policy creates a significant advantage for U.S.-based pharmaceutical companies and their supply chains, which are poised for growth as reliance on imports decreases.
Published: 26 September 2025
Explore BasketNavigating Pharma Price Controls
President Trump's ultimatum to major pharmaceutical firms to lower drug prices creates significant market uncertainty for brand-name drug makers. This situation could benefit companies that thrive on reducing healthcare costs, such as generic drug manufacturers and prescription discount platforms.
Published: 4 August 2025
Explore BasketWhy You’ll Want to Watch This Stock
Volume & Scale
Teva’s large manufacturing footprint drives cost advantages in generics, which can support margins — though pricing pressure and competition remain important caveats.
Speciality Pipeline Focus
Selective branded assets and R&D in areas like CNS could offer upside if successful, but development outcomes and regulatory hurdles create uncertainty.
Balance Sheet Watch
Investors often focus on debt reduction and cash flow recovery; improvements can strengthen prospects, while unresolved liabilities can limit flexibility.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
